SHR-1702

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameSHR-1702
Drug Alias NameSHR-1702
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionHepatitis A virus cellular receptor 2 inhibitors
TargetsHepatitis A virus cellular receptor 2
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesJiangsu Hengrui Medicine Co LtdShanghai Hengrui Pharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Hengrui Pharmaceutical Co LtdSuzhou Suncadia Biopharmaceuticals Co LtdJiangsu Hengrui Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A